Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Charles River Laboratories Intl (NY: CRL )

211.60 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jun 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 211.60
Bid (Size) 84.64 (2)
Ask (Size) 249.23 (2)
Prev. Close 211.60
Today's Range 211.60 - 211.60
52wk Range 161.65 - 275.00
Shares Outstanding 50,396,622
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives
From Charles River Laboratories International, Inc.
Via Business Wire

Performance

YTD
-9.67%
-9.67%
1 Month
-2.58%
-2.58%
3 Month
-20.33%
-20.33%
6 Month
-11.16%
-11.16%
1 Year
+2.57%
+2.57%

More News

Read More
The Analyst Verdict: Charles River In The Eyes Of 4 Experts
Via Benzinga
The Analyst Landscape: 7 Takes On Charles River
Via Benzinga
Evaluating Charles River: Insights From 7 Financial Analysts
Via Benzinga
Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at William Blair and Jefferies Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
From Charles River Laboratories International, Inc.
Via Business Wire
CRL Stock Earnings: Charles River Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Charles River Laboratories Announces First-Quarter 2024 Results
From Charles River Laboratories International, Inc.
Via Business Wire
The 7 Best Growth Stocks to Buy in May 2024
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River to Perform Plasmid Production for Ship of Theseus
From Charles River Laboratories International, Inc.
Via Business Wire
CHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Publishes 2023 Corporate Citizenship Report
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.